Grace Therapeutics, Inc. Current Liabilities
Grace Therapeutics, Inc. (GRCE) had Current Liabilities of $1.25 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Liabilities, Current $1.25M.
- 2026-03-31: Liabilities, Current $2.15M.
- 2025-12-31: Liabilities, Current $1.28M.
- 2025-09-30: Liabilities, Current $1.25M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $1.25M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.15M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $1.28M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $1.25M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.31M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.93M 10-K · filed 2026-06-18 |
| 2024-12-31 | $1.97M 10-Q · filed 2025-02-13 |
| 2024-09-30 | $2.67M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.60M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $1.68M 10-K · filed 2025-06-23 |
| 2023-12-31 | $1.77M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $1.40M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.97M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $3.41M 10-K · filed 2024-06-21 |
| 2022-12-31 | $3.43M 10-Q · filed 2023-02-14 |
| 2022-09-30 | $3.81M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.71M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.26M 10-K · filed 2023-06-23 |
| 2021-12-31 | $2.90M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $4.48M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $2.35M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.58M 10-K · filed 2022-06-21 |
| 2020-12-31 | $2.25M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $3.75M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $5.98M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $7.39M 10-K · filed 2021-06-22 |
| 2019-03-31 | $13.67M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |